In a letter to shareholders on Tuesday (August 13), the CEO of San Diego-based CV Sciences (OTCQB:CVSI) defended his company following a double-digit share price drop.

Joseph Dowling, CEO of the hemp-derived cannabidiol (CBD) manufacturer, wrote that the company is disappointed in the market’s reaction to the release of CV Sciences’ Q2 2019 financial report last Tuesday (August 6). During the period, the company achieved its 14th consecutive quarter of revenue growth.


Despite the positive results, the firm had suffered a significant share price drop of nearly 25 percent as of the closing bell on Monday (August 12). This came following commentary from Dowling indicating that the CBD market is set to gain more competitors, which will affect the margin lines for CV Sciences.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Dowling offered his commentary on competition in the space during a conference call with analysts and investors to discuss the Q2 results. During the call, the executive projected that CV Sciences may face stiffer competition in the CBD producer market.

“We pride ourselves on giving comprehensive quarterly updates, and our discussion of increased competition reflects what we see in our business today,” Dowling wrote in his letter, which was published after the call. “But, as I noted on our second quarter conference call, incremental competition may lead to choppy quarter to quarter results.”

Following Dowling’s letter this Tuesday, the company’s share price jumped back up, opening at US$3.10. As of 2:59 p.m. EDT that day, CV Sciences was trading at US$3.42, an 11.2 percent surge.

As part of its Q2 financials, CV Sciences reported US$16.9 million in revenue — up from US$14.9 million for the previous quarter — and total net income for the quarter of US$1.2 million.

The financials for the company during the quarter saw a downturn compared to Q2 2018, mainly due to increased investment in sales, marketing and research and development activities.

During the quarter, the company reported adjusted earnings before interest, taxes, depreciation and amortization of US$3.6 million.

Dowling believes any increase in competition will not slow the burgeoning CBD market in the US.

In May, a report co-written by BDS Analytics and Arcview Market Research indicated that the collective CBD market could reach US$20 billion in sales across the US by 2024.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“We’re witnessing CBD maturing from a cannabis sub-category into a full-blown industry of its own,” Roy Bingham, co-founder and CEO of BDS Analytics, said in a press release.

The US market can credit the rush for these CBD products to the passing of the farm bill late in 2018, which simultaneously legalized hemp and its derivatives.

CV Sciences, which produces CBD oil under its flagship brand PlusCBD Oil, has made it clear to investors that it wishes to uplist to a senior US exchange.

During the call with investors, the company announced it has retained the services of “special legal counsel” to aid in securing a NASDAQ listing. In July 2018, CV Sciences confirmed that it had filed an application for a NASDAQ listing.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Harvest Health & Recreation Inc. (OTCQX: HRVSF) to Trulieve Cannabis Corp. is fair to Harvest Health shareholders. Under the terms of the agreement, Harvest shareholders will receive 0.1170 of a subordinate voting share of Trulieve for each Harvest subordinate voting share (or equivalent) held.

Halper Sadeh encourages Harvest Health shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com .

Keep reading... Show less

Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”), an established Canadian cannabis and vape retailer, announced today the appointment of Cameron Wickham as a Director, Chief Executive Officer and Corporate Secretary of the Company and Ankit Gosain as Chief Financial Officer of the Company, effective May 7, 2021.

Daniel Pelchovitz, the Company’s former Chief Executive Officer, will continue with Spyder as a Director of the Company and as Chief Executive Officer of Spyder Cannabis Subco Inc., the Company’s Alcohol and Gaming Commission of Ontario (AGCO)-licensed, wholly-owned subsidiary that currently operates a cannabis dispensary in Niagara Falls, Ontario and has submitted two additional Retail Store Authorizations to the AGCO, and The Green Spyder Inc., the Company’s Alberta Gaming, Liquor & Cannabis (AGLC)-licensed, wholly-owned subsidiary that currently operates a cannabis dispensary in Calgary, Alberta.

Keep reading... Show less

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”) , a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2021 . All financial information is provided in U.S. dollars unless otherwise indicated.

1Q 2021 Financial Highlights (Unaudited)

Keep reading... Show less

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Harvest Health & Recreation Inc. (“Harvest” or the “Company”) (OTC: HRVSF) in connection with the proposed acquisition of the Company by Trulieve Cannabis Corp. (“Trulieve”) (OTC: TCNNF). Under the terms of the merger agreement, Harvest shareholders will receive 0.1170 shares of Trulieve common stock for each Harvest share that they own, representing implied per-share merger consideration of approximately $4.79 based upon Trulieve’s May 7, 2021 closing price of $40.92 . Upon consummation of the transaction, current Harvest shareholders will own only 26.7% of the issued and outstanding pro forma Trulieve shares.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at Canaccord Genuity’s 5th Annual Global Cannabis Conference on Tuesday, May 11, 2021 at 2:30 p.m. EDT.

Participants may access a live webcast of the presentation by going to the Upcoming Events page at thecronosgroup.com . A replay will be made available shortly following the live presentation.

Keep reading... Show less